臨床試験サービス市場 – 2030年までの世界予測

Report Overview

The global clinical trial services market is projected to reach USD 101.86 billion in 2030 from USD 66.59 billion in 2025, growing at a CAGR of 8.9% during the forecast period.

世界の臨床試験サービス市場は、予測期間中に年平均成長率8.9%で成長し、2025年の665億9,000万米ドルから2030年には1,018億6,000万米ドルに達すると予測されています。

This market is expanding as pharmaceutical, biotechnology, and medical device companies are increasingly outsourcing their clinical research activities to Contract Research Organizations (CROs). Flexible service models, such as Functional Service Provider (FSP) and hybrid service delivery models, offered by CROs enable cost management while allowing companies to retain control over critical operations.

製薬、バイオテクノロジー、医療機器企業が臨床研究活動を契約研究機関 (CRO) にアウトソーシングするケースが増えているため、この市場は拡大しています。CRO が提供する機能サービスプロバイダー (FSP) やハイブリッドサービス提供モデルなどの柔軟なサービスモデルにより、企業は重要な業務を管理しながらコスト管理が可能になります。

There is a growing demand for patient-centric trials, leveraging decentralized models, wearable devices, and digital platforms to enhance patient participation and retention. Technological advancements, including artificial intelligence (AI) and real-world data (RWD), are optimizing trial efficiency, site selection, and patient recruitment. The rising demand for personalized and precision medicine is driving an increase in clinical studies focused on targeted therapies, requiring CROs to support complex trial designs. Regulatory bodies are emphasizing pediatric clinical trials, requiring CROs to develop specialized expertise. Additionally, FDA guidelines promoting diversity in clinical trials are creating opportunities for CROs to expand patient recruitment and ensure broader representation. The increasing pipeline of new drug modalities, including cell and gene therapies, biologics, and RNA-based treatments, is further driving the need for specialized clinical research services.

“The oncology therapy area segment held the largest share in the clinical trial services market, by therapy area, during the forecast period”

In 2024, the oncology therapy area held the largest market within the clinical trial services market by therapy area. Factors such as the large number of cancer cases worldwide and the need for new treatments are supporting the large share of this therapy area. Cancer research is complex, requiring trials for targeted therapies, immunotherapies, and combination treatments. Regulatory agencies prioritize cancer drug approvals, leading to more trials in this area. Advances in precision medicine and biomarker research have also increased oncology trials, requiring expertise in patient recruitment and trial management. Strong investments from pharmaceutical companies, government agencies, and patient organizations further drive cancer research, making oncology the leading segment in clinical trials.

“The pharmaceutical & biopharmaceutical companies end user segment held the largest market share in the clinical trials services market, by end user, during the forecast period”

Pharmaceutical and biopharmaceutical companies dominated the clinical trial services end-user/sponsor market during the forecast period. Conducting in-house trials demands substantial investments in infrastructure, personnel, and regulatory compliance, making outsourcing a more cost-effective and efficient alternative as trial complexity increases. Partnering with Contract Research Organizations (CROs) allows these companies to leverage expertise in trial design, patient recruitment, regulatory adherence, and data management, expediting drug development. Additionally, the expanding R&D pipeline and growing focus on precision medicine have led pharmaceutical companies to outsource clinical services and laboratory testing, minimizing operational burdens and optimizing resources.

“Asia Pacific: The fastest growing region in the clinical trial services market”

The Asia Pacific clinical trial services market is projected to register the highest growth rate during the forecast period. This high growth is attributed to its large patient pool, high incidence of chronic and infectious diseases, and growing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly shifting manufacturing and clinical research to the region to benefit from cost advantages, regulatory improvements, and better patient retention in trials. Additionally, government support and increasing investments in clinical research have further driven the outsourcing of clinical trial activities to APAC, contributing to its strong market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 44%, Tier 2 – 32%, and Tier 3 – 24%
• By Designation: (Managers) – 45%, (CXOs, Directors)- 30%, and(Executives) – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Fortrea (US)
• ICON Plc (Ireland)
• Syneos Health (US)
• Laboratory Corporation of America Holdings (US)
• Medpace (US)
• Wuxi AppTec (China)
• Frontage Labs (US)
• Pharmaron (US)
• Tigermed (China)
• SGS Société Générale De Surveillance SA. (Switzerland)
• Eurofins Scientific (Luxembourg)
• Linical (Japan)
• Parexel International Corporation (US)
• Worldwide Clinical Trials (US)
• Novotech (Australia)
• PSI (Switzerland)
• Allucent (US)
• Premier Research (US)
• Clario (US)
• KCR S.A. (US)
• Rho, Inc. (US)
• Advanced Clinical (US)

Research Coverage:

This report provides a detailed picture of the global clinical trial service market. It aims to estimate the size and future growth potential of the market across different segments such as the service type, therapy area, phase, delivery model, modality, end user/sponsor, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial services market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new service launches, mergers and acquisitions, and recent developments associated with the clinical trial services market. Competitive analysis of upcoming startups in the clinical trial services market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall clinical trial services market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing focus on patient-centric trials (DCTs), increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing, rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities, service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid) and technological integrations), opportunities (Increased focus on pediatric clinical trials, regulatory requirement for increasing diversity in clinical trials, growing role of real-world evidence in drug approvals, expanding drug modalities (such as CGT, ADCs, Bispecific Abs) in clinical trials), and challenges (Cybersecurity or intellectual property concerns, and challenge of patient retention) influencing the growth of the clinical trial services market.
• Service Development/Innovation: Detailed insights on upcoming technologies, and new service launches in the clinical trial services market
• Market Development: Comprehensive information about lucrative markets – the report analyses the clinical trial services market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the clinical trial services market

Table of Contents

1               INTRODUCTION              45

1.1           STUDY OBJECTIVES       45

1.2           MARKET DEFINITION   45

1.3           STUDY SCOPE   46

1.3.1        MARKETS COVERED       46

1.3.2        REGIONAL SCOPE            47

1.3.3        INCLUSIONS AND EXCLUSIONS 47

1.3.4        YEARS CONSIDERED      49

1.4           CURRENCY CONSIDERED            49

1.5           STAKEHOLDERS               49

1.6           SUMMARY OF CHANGES               50

2               RESEARCH METHODOLOGY       51

2.1           RESEARCH DATA              51

2.1.1        SECONDARY DATA          52

2.1.2        PRIMARY DATA 52

2.2           GLOBAL MARKET ESTIMATION 53

2.2.1        MARKET ESTIMATION METHODOLOGY               53

2.2.1.1    Insights from primary experts             56

2.2.2        SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)       57

2.3           MARKET GROWTH RATE PROJECTION  58

2.4           DATA TRIANGULATION                60

2.5           RESEARCH ASSUMPTIONS           61

2.6           RESEARCH LIMITATIONS             62

3               EXECUTIVE SUMMARY  63

4               PREMIUM INSIGHTS       68

4.1           ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CLINICAL TRIAL SERVICES MARKET        68

4.2           NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND

COUNTRY (2024)               69

4.3           CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE (2025 VS. 2030)   69

4.4           CLINICAL TRIAL SERVICES MARKET, BY END USER (2024)    70

4.5           CLINICAL TRIAL SERVICES MARKET, BY COUNTRY                 70

5               MARKET OVERVIEW       71

5.1           INTRODUCTION              71

5.2           MARKET DYNAMICS       71

5.2.1        DRIVERS               72

5.2.1.1    Increasing focus on patient-centric trials (DCTs)          72

5.2.1.2    Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing                73

5.2.1.3    Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities 74

5.2.1.4    Service flexibility offered by CROs for clinical development

(FSP, FSO, Hybrid)             75

5.2.1.5    Technological integrations  76

5.2.2        OPPORTUNITIES              76

5.2.2.1    Increased focus on pediatric clinical trials        76

5.2.2.2    Increasing regulatory requirements for increasing diversity in clinical trials          77

5.2.2.3    Growing role of real-world evidence in drug approvals 78

5.2.2.4    Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials          79

5.2.3        CHALLENGES    80

5.2.3.1    Cybersecurity or intellectual property concerns              80

5.2.3.2    Challenge of patient retention            80

5.2.3.3    Growing market competition              81

5.3           MARKET TRENDS             81

5.3.1        IN SILICO CLINICAL TRIALS        81

5.4           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            81

5.5           PRICING ANALYSIS          82

5.5.1        PRICING ANALYSIS, BY KEY PLAYER (QUALITATIVE)                 82

5.5.2        INDICATIVE PRICING ANALYSIS, BY PHASE, 2024                 83

5.5.3        INDICATIVE PRICING ANALYSIS, BY THERAPEUTIC AREA, 2024           84

5.6           VALUE CHAIN ANALYSIS               84

5.7           ECOSYSTEM ANALYSIS  86

5.8           INVESTMENT AND FUNDING SCENARIO               88

5.9           TECHNOLOGY ANALYSIS             89

5.9.1        KEY TECHNOLOGIES     89

5.9.1.1    Clinical trial management system (CTMS)      89

5.9.1.2    Electronic data capture (EDC) systems            89

5.9.1.3    Randomization and trial supply management (RTSM) 90

5.9.2        COMPLEMENTARY TECHNOLOGIES       91

5.9.2.1    Telemedicine and wearable devices  91

5.9.2.2    AI and ML integration         91

5.10         KEY CONFERENCES AND EVENTS, 2025–2026        92

5.11         REGULATORY LANDSCAPE         93

5.11.1      REGULATORY FRAMEWORK       93

5.11.1.1  North America      93

5.11.1.2  Europe   94

5.11.1.3  Asia Pacific            94

5.11.1.4  RoW        95

5.11.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             96

5.12         PORTER’S FIVE FORCES ANALYSIS           103

5.12.1      THREAT OF NEW ENTRANTS      104

5.12.2      THREAT OF SUBSTITUTES          105

5.12.3      BARGAINING POWER OF SUPPLIERS       105

5.12.4      BARGAINING POWER OF BUYERS             105

5.12.5      INTENSITY OF COMPETITIVE RIVALRY 105

5.13         KEY STAKEHOLDERS AND BUYING CRITERIA     106

5.13.1      KEY STAKEHOLDERS IN BUYING PROCESS           106

5.13.2      BUYING CRITERIA           107

5.14         IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET               109

5.14.1      INTRODUCTION              109

5.14.2      MARKET POTENTIAL FOR CLINICAL TRIALS       109

5.14.3      AI USE CASES     110

5.14.4      KEY COMPANIES IMPLEMENTING AI      111

5.14.5      FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM       111

6               CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE                 112

6.1           INTRODUCTION              113

6.2           CLINICAL TRIAL MANAGEMENT & MONITORING                 114

6.2.1        RISING ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH                 114

6.3           LABORATORY SERVICES               117

6.3.1        ANALYTICAL TESTING SERVICES              121

6.3.1.1    Increasing demand for analytical testing for drug development to drive market          121

6.3.2        BIOANALYTICAL TESTING SERVICES      124

6.3.2.1    Rising focus on biologics in advanced therapies to drive market                 124

6.4           CLINICAL TRIAL DATA MANAGEMENT SERVICES                 127

6.4.1        BIOSTATISTICS 131

6.4.1.1    Integration of real-world data (RWD) into statistical analysis to support market growth        131

6.4.2        OTHER DATA MANAGEMENT SERVICES                134

6.5           CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES                 137

6.5.1        COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET  137

6.6           CONSULTING    140

6.6.1        INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET               140

6.7           PATIENT RECRUITMENT & RETENTION                143

6.7.1        INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH                 143

6.8           MEDICAL WRITING         145

6.8.1        INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET                 145

6.9           SAFETY & PHARMACOVIGILANCE            148

6.9.1        REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH       148

6.10         OTHER SERVICE TYPES 151

7               CLINICAL TRIAL SERVICES MARKET, BY PHASE 154

7.1           INTRODUCTION              155

7.2           PHASE III             156

7.2.1        HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING  156

7.3           PHASE II               159

7.3.1        LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS   159

7.4           PHASE I                 162

7.4.1        DECLINING TRIALS TO POSE CHALLENGE IN MARKET GROWTH             162

7.5           PHASE IV              166

7.5.1        SIGNIFICANCE OF PHASE IV FROM REGULATORY VIEWPOINT TO SUPPORT MARKET GROWTH    166

8               CLINICAL TRIAL SERVICES MARKET, BY MODALITY                 169

8.1           INTRODUCTION              170

8.2           SMALL MOLECULES       170

8.2.1        EXTENSIVE PIPELINE OF DRUGS IN DEVELOPMENT PHASE AND GROWING INVESTMENTS IN R&D OF SMALL MOLECULES TO BOOST MARKET GROWTH        170

8.3           BIOLOGICS         174

8.3.1        GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND RISING REGULATORY SUPPORT TO PROPEL DEMAND             174

8.4           MEDICAL DEVICES & IVD             177

8.4.1        SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND             177

9               CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA     180

9.1           INTRODUCTION              181

9.2           ONCOLOGY        182

9.2.1        GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET               182

9.3           NEUROLOGY     187

9.3.1        INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET             187

9.4           RESPIRATORY DISORDERS          190

9.4.1        RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH     190

9.5           METABOLIC DISORDERS/ENDOCRINOLOGY      193

9.5.1        INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH           193

9.6           CARDIOVASCULAR SYSTEM DISORDERS               197

9.6.1        HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET                 197

9.7           DERMATOLOGY               200

9.7.1        GROWING FOCUS ON DRUG DEVELOPMENT FOR VARIOUS SKIN CONDITIONS TO SUPPORT MARKET GROWTH                 200

9.8           GASTROINTESTINAL DISEASES 203

9.8.1        EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET               203

9.9           IMMUNOLOGICAL DISORDERS 206

9.9.1        GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS

TO FUEL MARKET GROWTH       206

9.10         INFECTIOUS DISEASES 209

9.10.1      RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET                 209

9.11         PSYCHIATRY      212

9.11.1      GROWING INCIDENCE OF PSYCHIATRIC DISORDERS

TO SUPPORT MARKET GROWTH              212

9.12         OPHTHALMOLOGY         215

9.12.1      RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS

TO SUPPORT SEGMENT GROWTH         215

9.13         HEMATOLOGY 218

9.13.1      CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH                 218

9.14         GENITOURINARY & WOMEN’S HEALTH 221

9.14.1      RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN

TO PROPEL MARKET      221

9.15         OTHER THERAPEUTIC AREAS    224

10            CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL 228

10.1         INTRODUCTION              229

10.2         FULL-SERVICE OUTSOURCING (FSO) MODEL    229

10.2.1      RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES

TO DRIVE MARKET         229

10.3         FUNCTIONAL SERVICE PROVIDER (FSP) MODEL                 233

10.3.1      GROWING ADOPTION OF FSP SERVICE BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH                 233

10.4         HYBRID MODEL                236

10.4.1      HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO

SUPPORT MARKET GROWTH     236

11            CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN                 239

11.1         INTRODUCTION              240

11.2         INTERVENTIONAL          240

11.2.1      MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET      240

11.3         OBSERVATIONAL             244

11.3.1      INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH              244

12            CLINICAL TRIAL SERVICES MARKET, BY END USER                 247

12.1         INTRODUCTION              248

12.2         PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES       248

12.2.1      INCREASE IN R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET                 248

12.3         MEDICAL DEVICE COMPANIES 253

12.3.1      RISING ACQUISITIONS AND EXPANSIONS OF SERVICE PORTFOLIOS

BY MEDICAL DEVICE CRO SERVICE PROVIDERS TO DRIVE MARKET               253

12.4         ACADEMIC INSTITUTES                256

12.4.1      RISING COLLABORATIONS BETWEEN CROS AND ACADEMIA

TO DRIVE MARKET         256

13            CLINICAL TRIAL SERVICES MARKET, BY REGION                 259

13.1         INTRODUCTION              260

13.2         NORTH AMERICA             260

13.2.1      US           266

13.2.1.1  Presence of well-established CROs to drive market       266

13.2.2      CANADA               271

13.2.2.1  Favorable government-led initiatives and rising R&D investments to drive market                271

13.3         EUROPE               276

13.3.1      GERMANY           281

13.3.1.1  Growing R&D spending and favorable government policies to propel market        281

13.3.2      UK          286

13.3.2.1  Rising collaborations and improved policies to support market                 286

13.3.3      FRANCE                291

13.3.3.1  Government-led support for effective drug research to drive market    291

13.3.4      ITALY    296

13.3.4.1  Government-led focus on improving clinical trial regulations to drive market          296

13.3.5      SPAIN    300

13.3.5.1  Rising R&D expenditure to boost market growth            300

13.3.6      REST OF EUROPE             304

13.4         ASIA PACIFIC     309

13.4.1      CHINA  315

13.4.1.1  Low manufacturing cost and increased establishment of R&D centers to drive market        315

13.4.2      INDIA    320

13.4.2.1  Cost-efficient and innovation-driven approach to propel market                 320

13.4.3      JAPAN   325

13.4.3.1  Decline in number of clinical trials to limit market         325

13.4.4      AUSTRALIA         330

13.4.4.1  Favorable tax incentives and cash rebates to pharmaceutical companies to support market              330

13.4.5      SOUTH KOREA  335

13.4.5.1  Favorable government initiatives for drug development to drive market    335

13.4.6      REST OF ASIA PACIFIC   340

13.5         LATIN AMERICA                344

13.5.1      BRAZIL 348

13.5.1.1  Government-led support through improved policies in pharmaceutical R&D to drive market                348

13.5.2      MEXICO                353

13.5.2.1  Increasing investments in pharma R&D to drive market                 353

13.5.3      REST OF LATIN AMERICA             356

13.6         MIDDLE EAST   361

13.6.1      GCC COUNTRIES              365

13.6.1.1  Saudi Arabia          369

13.6.1.1.1                Increase in collaborations to drive market        369

13.6.1.2  UAE        374

13.6.1.2.1                Growing clinical research activities to drive market                 374

13.6.1.3  Rest of GCC countries         377

13.6.2      REST OF MIDDLE EAST 382

13.6.3      AFRICA 386

13.6.3.1  Expanding pharmaceutical industry to support market growth                 386

14            COMPETITIVE LANDSCAPE         390

14.1         OVERVIEW          390

14.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            390

14.3         REVENUE ANALYSIS       393

14.4         MARKET SHARE ANALYSIS, 2024                 394

14.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 396

14.5.1      STARS   396

14.5.2      EMERGING LEADERS     396

14.5.3      PERVASIVE PLAYERS      397

14.5.4      PARTICIPANTS 397

14.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         398

14.5.5.1  Company footprint               398

14.5.5.2  Region footprint   399

14.5.5.3  Service type footprint           400

14.5.5.4  Phase footprint     401

14.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        402

14.6.1      PROGRESSIVE COMPANIES         402

14.6.2      RESPONSIVE COMPANIES            402

14.6.3      DYNAMIC COMPANIES  402

14.6.4      STARTING BLOCKS         403

14.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 404

14.6.5.1  Detailed list of key startups/SMEs    404

14.6.5.2  Competitive benchmarking of startups/SMEs 405

14.7         COMPANY VALUATION AND FINANCIAL METRICS                 406

14.8         BRAND/SERVICE COMPARISON 407

14.9         COMPETITIVE SCENARIO             408

14.9.1      SERVICE LAUNCHES       408

14.9.2      DEALS  409

14.9.3      EXPANSIONS     410

15            COMPANY PROFILES      411

15.1         KEY PLAYERS     411

15.1.1      IQVIA INC.           411

15.1.1.1  Business overview 411

15.1.1.2  Services offered     412

15.1.1.3  Recent developments           414

15.1.1.3.1                Service launches   414

15.1.1.3.2                Deals      414

15.1.1.3.3                Expansions             416

15.1.1.4  MnM view              417

15.1.1.4.1                Right to win           417

15.1.1.4.2                Strategic choices   417

15.1.1.4.3                Weaknesses and competitive threats 417

15.1.2      ICON PLC             418

15.1.2.1  Business overview 418

15.1.2.2  Services offered     419

15.1.2.3  Recent developments           426

15.1.2.3.1                Service launches   426

15.1.2.3.2                Deals      426

15.1.2.4  MnM view              427

15.1.2.4.1                Right to win           427

15.1.2.4.2                Strategic choices   427

15.1.2.4.3                Weaknesses and competitive threats 427

15.1.3      THERMO FISHER SCIENTIFIC INC.            428

15.1.3.1  Business overview 428

15.1.3.2  Services offered     429

15.1.3.3  Recent developments           435

15.1.3.3.1                Service launches   435

15.1.3.3.2                Deals      435

15.1.3.3.3                Expansions             437

15.1.3.4  MnM view              438

15.1.3.4.1                Right to win           438

15.1.3.4.2                Strategic choices   438

15.1.3.4.3                Weaknesses and competitive threats 438

15.1.4      FORTREA             439

15.1.4.1  Business overview 439

15.1.4.2  Services offered     440

15.1.4.3  Recent developments           444

15.1.4.3.1                Service launches   444

15.1.4.3.2                Deals      444

15.1.4.3.3                Expansions             445

15.1.4.4  MnM view              445

15.1.4.4.1                Right to win           445

15.1.4.4.2                Strategic choices   445

15.1.4.4.3                Weaknesses and competitive threats 445

15.1.5      SYNEOS HEALTH              446

15.1.5.1  Business overview 446

15.1.5.2  Services offered     447

15.1.5.3  Recent developments           448

15.1.5.3.1                Service launches   448

15.1.5.3.2                Deals      448

15.1.5.4  MnM view              451

15.1.5.4.1                Right to win           451

15.1.5.4.2                Strategic choices   451

15.1.5.4.3                Weaknesses and competitive threats 452

15.1.6      LABORATORY CORPORATION OF AMERICA HOLDINGS                 453

15.1.6.1  Business overview 453

15.1.6.2  Services offered     455

15.1.6.3  Recent developments           456

15.1.6.3.1                Service launches   456

15.1.6.3.2                Deals      456

15.1.6.3.3                Expansions             457

15.1.6.4  MnM view              458

15.1.6.4.1                Right to win           458

15.1.6.4.2                Strategic choices   458

15.1.6.4.3                Weaknesses and competitive threats 458

15.1.7      MEDPACE            459

15.1.7.1  Business overview 459

15.1.7.2  Services offered     460

15.1.8      WUXI APPTEC   463

15.1.8.1  Business overview 463

15.1.8.2  Services offered     464

15.1.8.3  Recent developments           467

15.1.8.3.1                Deals      467

15.1.9      FRONTAGE LABS              468

15.1.9.1  Business overview 468

15.1.9.2  Services offered     469

15.1.9.3  Recent developments           470

15.1.9.3.1                Deals      470

15.1.9.3.2                Expansions             471

15.1.10   PHARMARON     472

15.1.10.1                 Business overview 472

15.1.10.2                 Services offered     474

15.1.11   TIGERMED          475

15.1.11.1                 Business overview 475

15.1.11.2                 Services offered     476

15.1.11.3                 Recent developments           478

15.1.11.3.1             Service approvals  478

15.1.11.3.2             Deals      479

15.1.12   SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA 480

15.1.12.1                 Business overview 480

15.1.12.2                 Services offered     482

15.1.13   EUROFINS SCIENTIFIC  483

15.1.13.1                 Business overview 483

15.1.13.2                 Services offered     485

15.1.14   LINICAL                486

15.1.14.1                 Business overview 486

15.1.14.2                 Services offered     488

15.1.14.3                 Recent developments           488

15.1.14.3.1             Deals      488

15.1.14.3.2             Expansions             489

15.1.15   PAREXEL INTERNATIONAL CORPORATION         490

15.1.15.1                 Business overview 490

15.1.15.2                 Services offered     491

15.1.15.3                 Recent developments           492

15.1.15.3.1             Service launches   492

15.1.15.3.2             Deals      492

15.1.15.3.3             Expansions             494

15.2         OTHER PLAYERS              495

15.2.1      WORLDWIDE CLINICAL TRIALS 495

15.2.2      PROPHARMA     497

15.2.3      NOVOTECH        498

15.2.4      PSI          501

15.2.5      ALLUCENT          502

15.2.6      PREMIER RESEARCH       503

15.2.7      CAIDYA 504

15.2.8      ERGOMED GROUP           505

15.2.9      CLARIO 507

15.2.10   PRECISION MEDICINE GROUP, LLC.        508

15.2.11   ADVANCED CLINICAL   509

15.2.12   EPS HOLDINGS, INC.      510

15.2.13   GUIRES INC. (PEPGRA)  511

15.2.14   KCR S.A.                512

16            APPENDIX           513

16.1         DISCUSSION GUIDE        513

16.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                518

16.3         CUSTOMIZATION OPTIONS        520

16.4         RELATED REPORTS         520

16.5         AUTHOR DETAILS           521

LIST OF TABLES

TABLE 1                IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS  59

TABLE 2                RISK ASSESSMENT           62

TABLE 3                CLINICAL TRIAL SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS           72

TABLE 4                INDICATIVE PRICING ANALYSIS OF CLINICAL TRIAL SERVICES,

BY PHASE, 2024 (USD)    83

TABLE 5                INDICATIVE PRICING ANALYSIS OF CLINICAL TRIAL SERVICES, BY THERAPEUTIC AREA, 2024 (USD)    84

TABLE 6                CLINICAL TRIAL SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM       87

TABLE 7                CLINICAL TRIAL SERVICES MARKET: KEY CONFERENCES AND EVENTS,

2025–2026              92

TABLE 8                NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  96

TABLE 9                EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  97

TABLE 10              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  98

TABLE 11              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 99

TABLE 12              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 99

TABLE 13              REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES  100

TABLE 14              CLINICAL TRIAL SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 103

TABLE 15              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES FOR END USER                 106

TABLE 16              BUYING CRITERIA FOR CLINICAL TRIAL SERVICES, BY END USER                108

TABLE 17              CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION)             113

TABLE 18              CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            115

TABLE 19              NORTH AMERICA: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     115

TABLE 20              EUROPE: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               116

TABLE 21              ASIA PACIFIC: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116

TABLE 22              LATIN AMERICA: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     116

TABLE 23              MIDDLE EAST: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117

TABLE 24              GCC COUNTRIES: CLINICAL TRIAL MANAGEMENT & MONITORING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     117

TABLE 25              EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS        118

TABLE 26              LABORATORY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            118

TABLE 27              NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            119

TABLE 28              EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            119

TABLE 29             ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            119

TABLE 30              LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 31              MIDDLE EAST: LABORATORY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 32              GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 33              LABORATORY SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION)                121

TABLE 34              ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)          122

TABLE 35              NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            122

TABLE 36              EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            122

TABLE 37              ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 38              LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 39              MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 40              GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            124

TABLE 41              BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            125

TABLE 42              NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 125

TABLE 43              EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            125

TABLE 44              ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 45              LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 126

TABLE 46              MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 47              GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 127

TABLE 48              EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS        127

TABLE 49              CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            129

TABLE 50              NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               129

TABLE 51              EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               129

TABLE 52              ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               130

TABLE 53              LATIN AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               130

TABLE 54              MIDDLE EAST: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               130

TABLE 55              GCC COUNTRIES: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               131

TABLE 56              CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            131

TABLE 57              CLINICAL TRIAL DATA MANAGEMENT SERVICES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY REGION, 2023–2030 (USD MILLION) 132

TABLE 58              NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               132

TABLE 59              EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2023–2030 (USD MILLION)                 133

TABLE 60              ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               133

TABLE 61              LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               133

TABLE 62              MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 63              GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 64              OTHER DATA MANAGEMENT SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            135

TABLE 65              NORTH AMERICA: OTHER DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               135

TABLE 66              EUROPE: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 67              ASIA PACIFIC: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 68              LATIN AMERICA: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 69              MIDDLE EAST: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 70              GCC COUNTRIES: OTHER DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 137

TABLE 71              CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            138

TABLE 72              NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               138

TABLE 73              EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 138

TABLE 74              ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 75              LATIN AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 76              MIDDLE EAST: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 77              GCC COUNTRIES: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               140

TABLE 78              CONSULTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            140

TABLE 79              NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 80              EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 81              ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 82              LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 83              MIDDLE EAST: CONSULTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 84              GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 85              PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            143

TABLE 86              NORTH AMERICA: PATIENT RECRUITMENT & RETENTION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               143

TABLE 87              EUROPE: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            144

TABLE 88              ASIA PACIFIC: PATIENT RECRUITMENT & RETENTION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION), BY COUNTRY, 2023–2030 (USD MILLION)        144

TABLE 89              LATIN AMERICA: PATIENT RECRUITMENT & RETENTION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 90              MIDDLE EAST: PATIENT RECRUITMENT & RETENTION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               145

TABLE 91              GCC COUNTRIES: PATIENT RECRUITMENT & RETENTION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               145

TABLE 92              MEDICAL WRITING SERVICE MARKET, BY REGION, 2023–2030 (USD MILLION)          146

TABLE 93              NORTH AMERICA: MEDICAL WRITING SERVICE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            146

TABLE 94              EUROPE: MEDICAL WRITING SERVICE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            146

TABLE 95              ASIA PACIFIC: MEDICAL WRITING SERVICE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 96              LATIN AMERICA: MEDICAL WRITING SERVICE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 97              MIDDLE EAST: MEDICAL WRITING SERVICE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 98              GCC COUNTRIES: MEDICAL WRITING SERVICE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 99              SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            149

TABLE 100            NORTH AMERICA: SAFETY & PHARMACOVIGILANCE SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               149

TABLE 101            EUROPE: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 149

TABLE 102            ASIA PACIFIC: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 150

TABLE 103            LATIN AMERICA: SAFETY & PHARMACOVIGILANCE SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               150

TABLE 104            MIDDLE EAST: SAFETY & PHARMACOVIGILANCE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       150

TABLE 105            GCC COUNTRIES: SAFETY & PHARMACOVIGILANCE SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               151

TABLE 106            OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            151

TABLE 107            NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 108            EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 109            ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 110            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LATIN AMERICA,

BY COUNTRY, 2023–2030 (USD MILLION)               153

TABLE 111            MIDDLE EAST: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 112            GCC COUNTRIES: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 113            CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)            155

TABLE 114            CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY REGION,

2023–2030 (USD MILLION)            157

TABLE 115            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION)                 157

TABLE 116            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 117            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION)                 158

TABLE 118            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION)                 158

TABLE 119            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION)                 158

TABLE 120            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2023–2030 (USD MILLION)                 159

TABLE 121            CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY REGION,

2023–2030 (USD MILLION)            160

TABLE 122            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION)                 160

TABLE 123            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY,

2023–2030 (USD MILLION)            161

TABLE 124            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION)                 161

TABLE 125            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION)                 161

TABLE 126            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION)                 162

TABLE 127            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2023–2030 (USD MILLION)                 162

TABLE 128            CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY REGION,

2023–2030 (USD MILLION)            163

TABLE 129            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION)                 164

TABLE 130            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION)   164

TABLE 131            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION)                 164

TABLE 132            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION)                 165

TABLE 133            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION)                 165

TABLE 134            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2023–2030 (USD MILLION)                 165

TABLE 135            CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY REGION,

2023–2030 (USD MILLION)            166

TABLE 136            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION)                 166

TABLE 137            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY,

2023–2030 (USD MILLION)            167

TABLE 138            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION)                 167

TABLE 139            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION)                 167

TABLE 140            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION)                 168

TABLE 141            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2023–2030 (USD MILLION)                 168

TABLE 142            CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   170

TABLE 143            CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION,

2023–2030 (USD MILLION)            171

TABLE 144            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,

BY REGION, 2023–2030 (USD MILLION)   171

TABLE 145            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)                 172

TABLE 146            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,

BY REGION, 2023–2030 (USD MILLION)   172

TABLE 147            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,

BY REGION, 2023–2030 (USD MILLION)   173

TABLE 148            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,

BY REGION, 2023–2030 (USD MILLION)   173

TABLE 149            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,

BY REGION, 2023–2030 (USD MILLION)   173

TABLE 150            CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION,

2023–2030 (USD MILLION)            174

TABLE 151            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)            175

TABLE 152            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION,

2023–2030 (USD MILLION)            175

TABLE 153            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)            175

TABLE 154            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)            176

TABLE 155            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)            176

TABLE 156            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)            176

TABLE 157            CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY REGION, 2023–2030 (USD MILLION)                 177

TABLE 158            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 177

TABLE 159            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD,

BY COUNTRY, 2023–2030 (USD MILLION)               178

TABLE 160            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD,

BY COUNTRY, 2023–2030 (USD MILLION)               178

TABLE 161            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES &

IVD, BY COUNTRY, 2023–2030 (USD MILLION)   178

TABLE 162            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES &

IVD, BY COUNTRY, 2023–2030 (USD MILLION)     179

TABLE 163            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2023–2030 (USD MILLION) 179

TABLE 164            CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            181

TABLE 165            NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040 182

TABLE 166            CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)            184

TABLE 167            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               184

TABLE 168            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 185

TABLE 169            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            185

TABLE 170            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            186

TABLE 171            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            186

TABLE 172            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               186

TABLE 173            CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)            188

TABLE 174            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               188

TABLE 175            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 188

TABLE 176            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            189

TABLE 177            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               189

TABLE 178            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            189

TABLE 179            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               190

TABLE 180            CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)            191

TABLE 181            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       191

TABLE 182            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               192

TABLE 183            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       192

TABLE 184            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       192

TABLE 185            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       193

TABLE 186            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       193

TABLE 187            CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION)       195

TABLE 188            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     195

TABLE 189            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            195

TABLE 190            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     196

TABLE 191            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     196

TABLE 192            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     196

TABLE 193            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)     197

TABLE 194            CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 198

TABLE 195            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     198

TABLE 196            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            198

TABLE 197            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 198            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 199            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 200            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     200

TABLE 201            CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY REGION,

2023–2030 (USD MILLION)            201

TABLE 202            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               201

TABLE 203            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 201

TABLE 204            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               202

TABLE 205            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             202

TABLE 206            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               202

TABLE 207            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               203

TABLE 208            CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY REGION, 2023–2030 (USD MILLION)   204

TABLE 209            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            204

TABLE 210            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 205

TABLE 211            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            205

TABLE 212            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            205

TABLE 213            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            206

TABLE 214            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            206

TABLE 215            CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)            207

TABLE 216            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            207

TABLE 217            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207

TABLE 218            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            208

TABLE 219            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            208

TABLE 220            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            208

TABLE 221            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            209

TABLE 222            CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)                 210

TABLE 223            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210

TABLE 224            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               210

TABLE 225            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               211

TABLE 226            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211

TABLE 227            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               211

TABLE 228            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 212

TABLE 229            CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY REGION,

2023–2030 (USD MILLION)            213

TABLE 230            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY,

BY COUNTRY, 2023–2030 (USD MILLION)               213

TABLE 231            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION)                 213

TABLE 232            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION)            214

TABLE 233            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY,

BY COUNTRY, 2023–2030 (USD MILLION)               214

TABLE 234            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION)            214

TABLE 235            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY,

BY COUNTRY, 2023–2030 (USD MILLION)               215

TABLE 236            CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,

2023–2030 (USD MILLION)            216

TABLE 237            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               216

TABLE 238            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            216

TABLE 239            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               217

TABLE 240            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               217

TABLE 241            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               217

TABLE 242            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               218

TABLE 243            CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY REGION,

2023–2030 (USD MILLION)            219

TABLE 244            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               219

TABLE 245            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 219

TABLE 246            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             220

TABLE 247            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               220

TABLE 248            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               220

TABLE 249            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               221

TABLE 250            CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,

BY REGION, 2023–2030 (USD MILLION)   222

TABLE 251            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)     222

TABLE 252            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)            222

TABLE 253            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)     223

TABLE 254            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)     223

TABLE 255            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)     223

TABLE 256            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)     224

TABLE 257            CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)                 225

TABLE 258            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            225

TABLE 259            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               225

TABLE 260            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            226

TABLE 261            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            226

TABLE 262            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            226

TABLE 263            OTHER THERAPEUTIC AREAS: CLINICAL TRIAL SERVICES MARKET FOR GCC COUNTRIES, BY COUNTRY, 2023–2030 (USD MILLION)       227

TABLE 264            CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            229

TABLE 265            CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY REGION, 2023–2030 (USD MILLION) 230

TABLE 266            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     230

TABLE 267            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     231

TABLE 268            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     231

TABLE 269            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     232

TABLE 270            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     232

TABLE 271            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     232

TABLE 272            CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2023–2030 (USD MILLION)            233

TABLE 273            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)               234

TABLE 274            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)     234

TABLE 275            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)               234

TABLE 276            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)               235

TABLE 277            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)               235

TABLE 278            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2023–2030 (USD MILLION)               235

TABLE 279            CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY REGION,

2023–2030 (USD MILLION)            236

TABLE 280            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,

BY COUNTRY, 2023–2030 (USD MILLION)               236

TABLE 281            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2023–2030 (USD MILLION)                 237

TABLE 282            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,

BY COUNTRY, 2023–2030 (USD MILLION)               237

TABLE 283            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,

BY COUNTRY, 2023–2030 (USD MILLION)               237

TABLE 284            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,

BY COUNTRY, 2023–2030 (USD MILLION)               238

TABLE 285            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,

BY COUNTRY, 2023–2030 (USD MILLION)               238

TABLE 286            CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            240

TABLE 287            CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN,

BY REGION, 2023–2030 (USD MILLION)   241

TABLE 288            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            241

TABLE 289            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)       242

TABLE 290            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            242

TABLE 291            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            243

TABLE 292            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            243

TABLE 293            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            243

TABLE 294            CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN,

BY REGION, 2023–2030 (USD MILLION)   244

TABLE 295            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            245

TABLE 296            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION) 245

TABLE 297            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            245

TABLE 298            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            246

TABLE 299            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            246

TABLE 300            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN, BY COUNTRY, 2023–2030 (USD MILLION)            246

TABLE 301            CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                248

TABLE 302            CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION)          250

TABLE 303            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   250

TABLE 304            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               251

TABLE 305            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   251

TABLE 306            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   252

TABLE 307            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   252

TABLE 308            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   252

TABLE 309            CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023–2030 (USD MILLION)            253

TABLE 310            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            254

TABLE 311            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 254

TABLE 312            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            254

TABLE 313            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            255

TABLE 314            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            255

TABLE 315            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            255

TABLE 316            CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION)                 256

TABLE 317            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 256

TABLE 318            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 319            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 320            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 257

TABLE 321            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2023–2030 (USD MILLION)               258

TABLE 322            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 258

TABLE 323          CLINICAL TRIAL SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            260

TABLE 324            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            262

TABLE 325            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            262

TABLE 326            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       263

TABLE 327            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            263

TABLE 328            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            263

TABLE 329            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 264

TABLE 330            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            265

TABLE 331            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)                 265

TABLE 332            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            265

TABLE 333            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            266

TABLE 334            US: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            267

TABLE 335            US: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            267

TABLE 336            US: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      268

TABLE 337            US: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             268

TABLE 338            US: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            269

TABLE 339            US: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   269

TABLE 340            US: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            270

TABLE 341            US: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            270

TABLE 342            US: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                270

TABLE 343            CANADA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            272

TABLE 344            CANADA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      272

TABLE 345            CANADA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       273

TABLE 346            CANADA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            273

TABLE 347            CANADA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            274

TABLE 348            CANADA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            274

TABLE 349            CANADA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            275

TABLE 350            CANADA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            275

TABLE 351            CANADA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            275

TABLE 352            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            276

TABLE 353            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            277

TABLE 354            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      277

TABLE 355            EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       278

TABLE 356            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            278

TABLE 357            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            279

TABLE 358            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            279

TABLE 359            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            280

TABLE 360            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            280

TABLE 361            EUROPE: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            280

TABLE 362            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            282

TABLE 363            GERMANY: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      282

TABLE 364            GERMANY: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       283

TABLE 365            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            283

TABLE 366            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            284

TABLE 367            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            284

TABLE 368            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            285

TABLE 369            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            285

TABLE 370            GERMANY: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            285

TABLE 371            UK: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            287

TABLE 372            UK: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            287

TABLE 373            UK: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      288

TABLE 374            UK: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             288

TABLE 375            UK: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            289

TABLE 376            UK: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   289

TABLE 377            UK: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            290

TABLE 378            UK: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            290

TABLE 379            UK: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            290

TABLE 380            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            292

TABLE 381            FRANCE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      292

TABLE 382            FRANCE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       293

TABLE 383            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            293

TABLE 384            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            294

TABLE 385            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            294

TABLE 386            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            295

TABLE 387            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            295

TABLE 388            FRANCE: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            295

TABLE 389            ITALY: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            296

TABLE 390            ITALY: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      297

TABLE 391            ITALY: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      297

TABLE 392            ITALY: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             297

TABLE 393            ITALY: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            298

TABLE 394            ITALY: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            298

TABLE 395            ITALY: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            299

TABLE 396            ITALY: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            299

TABLE 397            ITALY: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            299

TABLE 398            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            300

TABLE 399            SPAIN: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      301

TABLE 400            SPAIN: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      301

TABLE 401            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             301

TABLE 402            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            302

TABLE 403            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            302

TABLE 404            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            303

TABLE 405            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            303

TABLE 406            SPAIN: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            303

TABLE 407            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            305

TABLE 408            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       305

TABLE 409            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            306

TABLE 410            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            306

TABLE 411            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 307

TABLE 412            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            307

TABLE 413            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)                 308

TABLE 414            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            308

TABLE 415            REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            308

TABLE 416            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            311

TABLE 417            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      311

TABLE 418            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            312

TABLE 419            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            312

TABLE 420            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            313

TABLE 421            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            313

TABLE 422            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            314

TABLE 423            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            314

TABLE 424            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            314

TABLE 425            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            315

TABLE 426            CHINA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            316

TABLE 427            CHINA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      317

TABLE 428            CHINA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      317

TABLE 429            CHINA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             317

TABLE 430            CHINA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            318

TABLE 431            CHINA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            318

TABLE 432            CHINA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            319

TABLE 433            CHINA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            319

TABLE 434            CHINA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            319

TABLE 435            INDIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            321

TABLE 436            INDIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      321

TABLE 437            INDIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      322

TABLE 438            INDIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             322

TABLE 439            INDIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            323

TABLE 440            INDIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            323

TABLE 441            INDIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            324

TABLE 442            INDIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            324

TABLE 443            INDIA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            324

TABLE 444            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            326

TABLE 445            JAPAN: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      326

TABLE 446            JAPAN: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      327

TABLE 447            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             327

TABLE 448            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            328

TABLE 449            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            328

TABLE 450            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            329

TABLE 451            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)          329

TABLE 452            JAPAN: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            329

TABLE 453            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            331

TABLE 454            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      331

TABLE 455            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            332

TABLE 456            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            332

TABLE 457            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            333

TABLE 458            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            333

TABLE 459            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            334

TABLE 460            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            334

TABLE 461            AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            334

TABLE 462            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            336

TABLE 463            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       336

TABLE 464            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            337

TABLE 465            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            337

TABLE 466            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 338

TABLE 467            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            338

TABLE 468            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            339

TABLE 469            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            339

TABLE 470            SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            339

TABLE 471            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION)                 340

TABLE 472            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)                341

TABLE 473            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)             341

TABLE 474            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            341

TABLE 475            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            342

TABLE 476            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            342

TABLE 477            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)            343

TABLE 478            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION)            343

TABLE 479            REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            343

TABLE 480            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            344

TABLE 481            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       345

TABLE 482            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            345

TABLE 483            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            345

TABLE 484            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 346

TABLE 485            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            346

TABLE 486            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            347

TABLE 487            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            347

TABLE 488            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            347

TABLE 489            LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            348

TABLE 490            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            349

TABLE 491            BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      349

TABLE 492            BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       350

TABLE 493            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            350

TABLE 494            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            351

TABLE 495            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            351

TABLE 496            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            352

TABLE 497            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            352

TABLE 498            BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            352

TABLE 499            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            353

TABLE 500            MEXICO: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      354

TABLE 501            MEXICO: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       354

TABLE 502            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            354

TABLE 503            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            355

TABLE 504            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            355

TABLE 505            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            356

TABLE 506            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            356

TABLE 507            MEXICO: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            356

TABLE 508            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION)                 357

TABLE 509            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)                357

TABLE 510            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)             358

TABLE 511            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            358

TABLE 512            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            359

TABLE 513            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)                 359

TABLE 514            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)            360

TABLE 515            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION)            360

TABLE 516            REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 360

TABLE 517            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            361

TABLE 518            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      361

TABLE 519            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            362

TABLE 520            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            362

TABLE 521            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            363

TABLE 522            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            363

TABLE 523            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)          364

TABLE 524            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)          364

TABLE 525            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            364

TABLE 526            MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            365

TABLE 527            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            365

TABLE 528            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       366

TABLE 529            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            366

TABLE 530            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            366

TABLE 531            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 367

TABLE 532            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            367

TABLE 533            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)                 368

TABLE 534            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            368

TABLE 535            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            368

TABLE 536            GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            369

TABLE 537            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            370

TABLE 538            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       370

TABLE 539            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)            371

TABLE 540            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            371

TABLE 541            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            372

TABLE 542            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            372

TABLE 543            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            373

TABLE 544            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            373

TABLE 545            SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            373

TABLE 546            UAE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            374

TABLE 547            UAE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      375

TABLE 548            UAE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      375

TABLE 549            UAE: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2023–2030 (USD MILLION)             375

TABLE 550            UAE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            376

TABLE 551            UAE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            376

TABLE 552            UAE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            377

TABLE 553            UAE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            377

TABLE 554            UAE: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            377

TABLE 555            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION)                 378

TABLE 556            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)                378

TABLE 557            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)             379

TABLE 558            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            379

TABLE 559            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            380

TABLE 560            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)                 380

TABLE 561            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)            381

TABLE 562            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION)            381

TABLE 563            REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 381

TABLE 564            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2023–2030 (USD MILLION)                 382

TABLE 565            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)                383

TABLE 566            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)             383

TABLE 567            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            383

TABLE 568            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            384

TABLE 569            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            384

TABLE 570            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2023–2030 (USD MILLION)            385

TABLE 571            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2023–2030 (USD MILLION)            385

TABLE 572            REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            385

TABLE 573            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2023–2030 (USD MILLION)            386

TABLE 574            AFRICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,

BY SERVICE TYPE, 2023–2030 (USD MILLION)      387

TABLE 575            AFRICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2023–2030 (USD MILLION)       387

TABLE 576            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,

2023–2030 (USD MILLION)            387

TABLE 577            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            388

TABLE 578            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            388

TABLE 579            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,

2023–2030 (USD MILLION)            389

TABLE 580            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,

2023–2030 (USD MILLION)            389

TABLE 581            AFRICA: CLINICAL TRIAL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)          389

TABLE 582            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SERVICES MARKET, JANUARY 2021–JANUARY 2025    390

TABLE 583            CLINICAL TRIAL SERVICES MARKET: DEGREE OF COMPETITION, 2024                 395

TABLE 584            CLINICAL TRIAL SERVICES MARKET: REGION FOOTPRINT       399

TABLE 585            CLINICAL TRIAL SERVICES MARKET: SERVICE TYPE FOOTPRINT            400

TABLE 586            CLINICAL TRIAL SERVICES MARKET: PHASE FOOTPRINT       401

TABLE 587            CLINICAL TRIAL SERVICES MARKET: DETAILED LIST OF KEY STARTUP/SMES      404

TABLE 588            CLINICAL TRIAL SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES                 405

TABLE 589            CLINICAL TRIAL SERVICES MARKET: SERVICE LAUNCHES,

JANUARY 2021–JANUARY 2025   408

TABLE 590            CLINICAL TRIAL SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025     409

TABLE 591            CLINICAL TRIAL SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025         410

TABLE 592            IQVIA INC.: COMPANY OVERVIEW            411

TABLE 593            IQVIA INC.: SERVICES OFFERED 412

TABLE 594            IQVIA INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025    414

TABLE 595            IQVIA INC.: DEALS, JANUARY 2021–JANUARY 2025        414

TABLE 596            IQVIA INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025    416

TABLE 597            ICON PLC: COMPANY OVERVIEW             418

TABLE 598            ICON PLC: SERVICES OFFERED 419

TABLE 599            ICON PLC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025    426

TABLE 600            ICON PLC: DEALS, JANUARY 2021–JANUARY 2025                 426

TABLE 601            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          428

TABLE 602            THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED             429

TABLE 603            THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,

JANUARY 2021–JANUARY 2025     435

TABLE 604            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025     435

TABLE 605          THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025     437

TABLE 606            FORTREA: COMPANY OVERVIEW              439

TABLE 607            FORTREA: SERVICES OFFERED  440

TABLE 608            FORTREA: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025    444

TABLE 609            FORTREA: DEALS, JANUARY 2021–JANUARY 2025                 444

TABLE 610            FORTREA: EXPANSIONS, JANUARY 2021–JANUARY 2025    445

TABLE 611            SYNEOS HEALTH: COMPANY OVERVIEW                 446

TABLE 612            SYNEOS HEALTH: SERVICES OFFERED   447

TABLE 613            SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025     448

TABLE 614            SYNEOS HEALTH: DEALS, JANUARY 2021–JANUARY 2025    448

TABLE 615            LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW          453

TABLE 616            LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED               455

TABLE 617            LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025                 456

TABLE 618            LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS,

JANUARY 2021–JANUARY 2025     456

TABLE 619            LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS,

JANUARY 2021–JANUARY 2025     457

TABLE 620            MEDPACE: COMPANY OVERVIEW             459

TABLE 621            MEDPACE: SERVICES OFFERED 460

TABLE 622            WUXI APPTEC: COMPANY OVERVIEW    463

TABLE 623            WUXI APPTEC: SERVICES OFFERED         464

TABLE 624            WUXI APPTEC: DEALS, JANUARY 2021–JANUARY 2025        467

TABLE 625            FRONTAGE LABS: COMPANY OVERVIEW                 468

TABLE 626            FRONTAGE LABS: SERVICES OFFERED   469

TABLE 627            FRONTAGE LABS: DEALS, JANUARY 2021–JANUARY 2025    470

TABLE 628            FRONTAGE LABS: EXPANSIONS, JANUARY 2021–JANUARY 2025    471

TABLE 629            PHARMARON: COMPANY OVERVIEW     472

TABLE 630            PHARMARON: SERVICES OFFERED          474

TABLE 631            TIGERMED: COMPANY OVERVIEW          475

TABLE 632            TIGERMED: SERVICES OFFERED               476

TABLE 633            TIGERMED: SERVICE APPROVALS, JANUARY 2021–JANUARY 2025         478

TABLE 634            TIGERMED: DEALS, JANUARY 2021–JANUARY 2025        479

TABLE 635            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW   480

TABLE 636            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: SERVICES OFFERED        482

TABLE 637            EUROFINS SCIENTIFIC: COMPANY OVERVIEW                 483

TABLE 638            EUROFINS SCIENTIFIC: SERVICES OFFERED                 485

TABLE 639            LINICAL: COMPANY OVERVIEW                486

TABLE 640            LINICAL: SERVICES OFFERED     488

TABLE 641            LINICAL: DEALS, JANUARY 2021–JANUARY 2025                 488

TABLE 642            LINICAL: EXPANSIONS, JANUARY 2021–JANUARY 2025        489

TABLE 643            PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW   490

TABLE 644            PAREXEL INTERNATIONAL CORPORATION: SERVICES OFFERED        491

TABLE 645            PAREXEL INTERNATIONAL CORPORATION: SERVICE LAUNCHES,

JANUARY 2021–JANUARY 2025     492

TABLE 646            PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2021–JANUARY 2025      492

TABLE 647            PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS,

JANUARY 2021–JANUARY 2025     494

TABLE 648            WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW          495

TABLE 649            PROPHARMA: COMPANY OVERVIEW      497

TABLE 650            NOVOTECH: COMPANY OVERVIEW        498

TABLE 651            PSI: COMPANY OVERVIEW           501

TABLE 652            ALLUCENT: COMPANY OVERVIEW          502

TABLE 653            PREMIER RESEARCH: COMPANY OVERVIEW                 503

TABLE 654            CAIDYA: COMPANY OVERVIEW 504

TABLE 655            ERGOMED GROUP: COMPANY OVERVIEW                 505

TABLE 656            CLARIO: COMPANY OVERVIEW 507

TABLE 657            PRECISION MEDICINE GROUP, LLC: COMPANY OVERVIEW          508

TABLE 658            ADVANCED CLINICAL: COMPANY OVERVIEW                 509

TABLE 659            EPS HOLDINGS, INC.: COMPANY OVERVIEW                 510

TABLE 660            GUIRES INC. (PEPGRA): COMPANY OVERVIEW                 511

TABLE 661            KCR S.A.: COMPANY OVERVIEW 512

LIST OF FIGURES

FIGURE 1              CLINICAL TRIAL SERVICES MARKET: SEGMENTATION              46

FIGURE 2              CLINICAL TRIAL SERVICES MARKET: REGIONAL SCOPE  47

FIGURE 3              RESEARCH DESIGN         51

FIGURE 4              CLINICAL TRIAL SERVICES MARKET: BREAKDOWN OF PRIMARIES      53

FIGURE 5              GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024                 55

FIGURE 6              ILLUSTRATIVE EXAMPLE OF IQVIA, INC.: REVENUE SHARE ANALYSIS (2024)            55

FIGURE 7              CLINICAL TRIAL SERVICES MARKET SIZE ESTIMATION

(SUPPLY-SIDE ANALYSIS), 2024  54

FIGURE 8              MARKET SIZE VALIDATION FROM PRIMARY SOURCES             56

FIGURE 9              SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH           57

FIGURE 10            CLINICAL TRIAL SERVICES MARKET: CAGR PROJECTIONS   58

FIGURE 11            DATA TRIANGULATION METHODOLOGY                 60

FIGURE 12            CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,

2025 VS. 2030 (USD MILLION)      63

FIGURE 13            CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,

2025 VS. 2030 (USD MILLION)      64

FIGURE 14            CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024 (USD MILLION)                65

FIGURE 15            CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024 (USD MILLION)              65

FIGURE 16            CLINICAL TRIAL SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)         66

FIGURE 17            ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL TRIAL SERVICES MARKET DURING FORECAST PERIOD                67

FIGURE 18            GROWING DEMAND FOR PEDIATRIC CLINICAL TRIALS FOR VARIOUS MARKETED DRUGS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS     68

FIGURE 19            SMALL MOLECULES SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN CLINICAL TRIAL SERVICES MARKET IN 2024         69

FIGURE 20            CLINICAL TRIAL MANAGEMENT & MONITORING SEGMENT DOMINATED

MARKET IN 2030                69

FIGURE 21            PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT HELD LARGEST SHARE OF CLINICAL TRIAL SERVICES MARKET IN 2024              70

FIGURE 22            CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD       70

FIGURE 23            DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CLINICAL

TRIAL SERVICES MARKET             71

FIGURE 24            R&D SPEND OF LARGE PHARMACEUTICAL COMPANIES,

2014–2023 (USD BILLION)             74

FIGURE 25            BIOSIMILAR APPROVALS IN US, 2015–2024                 75

FIGURE 26            NUMBER OF CLINICAL TRIALS FOR VARIOUS MODALITIES     79

FIGURE 27            TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS   82

FIGURE 28            CLINICAL TRIAL SERVICES MARKET: VALUE CHAIN ANALYSIS              85

FIGURE 30            CLINICAL TRIAL SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 104

FIGURE 31            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES, BY END USER  106

FIGURE 32            KEY BUYING CRITERIA FOR CLINICAL TRIAL SERVICES, BY END USER                107

FIGURE 33            DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021–2024              155

FIGURE 34            PHASE III CLINICAL TRIALS, 2014–2024    156

FIGURE 35            PHASE II CLINICAL TRIALS, 2014–2024     159

FIGURE 36            PHASE I CLINICAL TRIALS, 2014–2024       163

FIGURE 37            NUMBER OF REGISTERED ONCOLOGY CLINICAL TRIALS, 2012–2024 (THOUSAND)          183

FIGURE 38            ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)                194

FIGURE 39            GLOBAL R&D PIPELINE, 2015–2024            249

FIGURE 40            R&D SPENDING BY LARGE PHARMA COMPANIES, 2015–2023 (USD BILLION)  249

FIGURE 41            NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET SNAPSHOT       261

FIGURE 42            ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET SNAPSHOT       310

FIGURE 43            CLINICAL TRIALS IN JAPAN, 1999–2024    325

FIGURE 44            CLINICAL TRIAL SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS,

2022–2024 (USD MILLION)            393

FIGURE 45            CLINICAL TRIAL SERVICES MARKET SHARE ANALYSIS, 2024  394

FIGURE 46            CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       397

FIGURE 47            CLINICAL TRIAL SERVICES MARKET: COMPANY FOOTPRINT       398

FIGURE 48            CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 403

FIGURE 49            CLINICAL TRIAL SERVICES MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 406

FIGURE 50            CLINICAL TRIAL SERVICES MARKET: EV/EBITDA OF KEY VENDORS, 2024 406

FIGURE 51            CLINICAL TRIAL SERVICES MARKET: BRAND/SERVICE COMPARISON 407

FIGURE 52            IQVIA INC.: COMPANY SNAPSHOT (2024)                 412

FIGURE 53            ICON PLC: COMPANY SNAPSHOT (2023)                 419

FIGURE 54            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)             429

FIGURE 55            FORTREA: COMPANY SNAPSHOT (2023)                 440

FIGURE 56            LABORATORY CORPORATION OF AMERICA HOLDINGS:

COMPANY SNAPSHOT (2023)      454

FIGURE 57            MEDPACE: COMPANY SNAPSHOT (2024)                 460

FIGURE 58            WUXI APPTEC: COMPANY SNAPSHOT (2023)                 464

FIGURE 59            FRONTAGE LABS: COMPANY SNAPSHOT (2023)                 469

FIGURE 60            PHARMARON: COMPANY SNAPSHOT (2023)                 473

FIGURE 61            TIGERMED: COMPANY SNAPSHOT (2023)                 476

FIGURE 62            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2023)      481

FIGURE 63            EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)    484

FIGURE 64            LINICAL: COMPANY SNAPSHOT (2023)   487

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• UV安定剤市場 – 2030年までの世界予測 2025-05-16
• 産業用通信市場 – 2030年までの世界予測 2025-05-16
• 経腸栄養装置市場 – 2030年までの世界予測 2025-05-15
• データセンターGPU市場 – 2030年までの世界予測 2025-05-15
• ステンレス鋼シームレスパイプ市場 – 2030年までの世界予測 2025-05-15

MarketsandMarkets  出版レポート一覧